SB531 would expand school-based emergency medication authority in Hawaii by allowing schools to maintain a stock supply of bronchodilators for use during actual or perceived asthma episodes. It directs the Department of Education, in collaboration with the Department of Health, to create a protocol covering storage, training, administration standards, and follow-up procedures, and it allows schools to obtain bronchodilators through prescriptions issued to the school, refills, donations, or transfers so long as the medications meet specified safety conditions.
The bill also broadens and reorganizes existing law on medication administration in schools. It authorizes trained school employees and agents, including school health assistants, to volunteer to administer or assist with a range of emergency and chronic-condition medications and care, including epinephrine, glucagon, seizure rescue medication, inhalers, insulin, blood glucose monitoring, and stock bronchodilators. It revises the student self-administration statute to streamline language, preserve students’ ability to carry needed medication and devices, and maintain liability protections for persons acting in compliance with the law, except in cases of gross negligence or intentional misconduct. Finally, it amends prescription labeling rules so bronchodilator prescriptions for school stock supplies can list the school or institution as the patient and include the school’s name and address.
In practical terms, the bill would affect Chapter 302A and Chapter 328 of the Hawaii Revised Statutes by creating new school-medication provisions and updating prescription-dispensing requirements. It would apply to public and private day care centers, child care facilities, Head Start programs, preschools, kindergartens, and elementary and secondary schools. The measure is aimed at improving emergency response capacity for asthma and other medical emergencies in school settings while setting training, documentation, and storage requirements for participating schools and staff.
The overall sentiment reflected in the bill materials is supportive of expanding school health preparedness, especially for asthma and other life-threatening conditions, but the measure was not advanced at the committee stage and was deferred by the Senate Committee on Education. No vote record or transcript discussion is provided, so there is no direct evidence of debate in the available context. The structure of the bill suggests a policy focus on safety, access, and liability protection rather than controversy over the underlying medical interventions.
The main points of potential contention are likely to involve implementation burdens, staff training, liability and indemnification provisions, and the decision to allow schools to stock and administer prescription bronchodilators to students who may not have a personal prescription. The bill also imposes parent notification and acknowledgment requirements, which may reflect concern about consent and risk management. Any opposition would likely center on school operational capacity, medical oversight, and whether the expanded authority should be limited to certain personnel or settings.
SB531 would add new sections to Chapter 302A governing stock bronchodilators and emergency medication administration in schools, and it would amend existing student self-administration provisions in section 302A-1164. It would also revise section 328-16 to permit bronchodilator prescriptions to identify a school or institution as the patient and to include school-specific labeling information. The bill would therefore change both education law and pharmacy labeling requirements, while extending liability protections to schools, employees, volunteers, and health professionals acting within the statute.
The available context suggests generally favorable policy intent toward improving school emergency response for asthma, diabetes, anaphylaxis, and seizures, with an emphasis on access to life-saving medication and staff training. However, the bill was deferred in the Senate Committee on Education, indicating it did not move forward at that stage. Because there are no transcripts or recorded votes, the public or committee-level sentiment cannot be measured beyond the bill’s protective and health-oriented design and its lack of advancement.
Likely areas of contention include whether schools should be permitted to maintain a stock supply of bronchodilators for any student with an actual or perceived asthma episode, how much training and protocol compliance should be required of school staff, and whether the liability waiver and indemnification language is appropriate. Another possible issue is the expansion of volunteer authority for school employees and agents to administer multiple medications and assist with chronic-condition care, which may raise concerns about workload, medical risk, and the scope of nonmedical personnel involvement. The bill’s requirement that parents acknowledge no-liability provisions for stock bronchodilator use may also be a point of concern.